Relapse/Refractory Multiple Myeloma
7 clinical trials · Condition
◉ Watch Relapse/Refractory Multiple Myeloma
| Record | Firm | Date |
|---|---|---|
| Safety, Activity and Cell Kinetics of CYAD-211 in Patients With Relapsed or Refractory Multiple Myeloma (NCT04613557) | Celyad Oncology SA | 2020-11-16 |
| A Study of Evaluating the Safety and Efficacy of ATG-010 in Relapsed Refractory Multiple Myeloma (NCT03944057) | Antengene Corporation | 2019-09-02 |
| Retrospective and Prospective Study of POmalidomide Plus LoW Dose Dexa Efficacy in RRMM Patients Under Real-Life Conditions (NCT03353545) | Genesis Pharma S.A. | 2017-11-16 |
| Clarithromycin,Lenalidomide and Dexamethasone for Relapsed/Refractory Myeloma (NCT02986451) | Sun Yat-sen University | 2016-12-01 |
| Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Japanese Patients With Relapsed/Refractory Multiple Myeloma (NCT02290431) | Novartis Pharmaceuticals | 2014-12-16 |
| Paclitaxel,Cyclophosphamide and Dexamethasone for Relapsed or Refractory Multiple Myeloma (NCT02985333) | Sun Yat-sen University | 2014-01-01 |
Track Relapse/Refractory Multiple Myeloma automatically
Every clearance here is in the API, with alerts when new ones post.